Aleksandra Rizo

Title: Innovations in Myelodysplastic Syndrome Treatment by Aleksandra Rizo

Introduction

Aleksandra Rizo is a notable inventor based in Raritan, NJ, who has made significant contributions to the field of medical treatment for myelodysplastic syndrome (MDS). With a total of three patents to her name, Rizo's work focuses on innovative methods for treating and monitoring this complex condition.

Latest Patents

Rizo's latest patents include groundbreaking methods for treating myelodysplastic syndrome. These methods involve monitoring therapeutic efficacy in subjects with MDS and identifying candidates for treatment with telomerase inhibitors. Specifically, her patents detail the administration of an effective amount of a telomerase inhibitor, such as imetelstat sodium, and the assessment of hTERT expression levels in biological samples. A significant finding is that a 50% or greater reduction in hTERT expression levels can indicate a subject's increased likelihood of benefiting from treatment. The patents also address subjects classified as having low or intermediate-1 IPSS risk MDS and those who are relapsed or refractory to Erythropoiesis-Stimulating Agents.

Career Highlights

Rizo is currently employed at Geron Corporation, where she continues to advance her research and development efforts in the treatment of MDS. Her work is characterized by a commitment to improving patient outcomes through innovative therapeutic strategies.

Collaborations

Rizo collaborates with esteemed colleagues, including Jacqueline C Bussolari and Fei Huang, to further enhance the research and development of effective treatments for myelodysplastic syndrome.

Conclusion

Aleksandra Rizo's contributions to the field of myelodysplastic syndrome treatment exemplify the impact of innovative research in medicine. Her patents and ongoing work at Geron Corporation highlight her dedication to improving therapeutic options for patients suffering from this challenging condition.